|
Lazaro Sanchez AD, Benitez Fuentes JD, Gil GL, Garcia MTG, Moreno EF, Zamora PC, Yago JB, Mohamed KM, Arroyo Rodriguez AB. Clinical and Proteomic Insights into a Cytokine Release Syndrome Triggered by Tebentafusp in a Metastatic Uveal Melanoma Patient: Case Report. J Clin Med. 2025 Feb 17;14(4):1333. doi: 10.3390/jcm14041333. PubMed PMID: 40004863; PubMed Central PMCID: PMC11856639.
AÑO: 2025; IF: 3.0
|
40004863
|
Sanchez-Espinosa A, Garcia-Rodriguez J, Alonso-Aguirre V, Acosta-Ortega JM, Conesa-Zamora P, Garcia-Solano J, Luengo-Gil G. Expression of Fascin and DNA Topoisomerase 2-Alpha in Breast Carcinoma: Correlation with Histological Subtypes and Other Prognostic Markers. Int J Mol Sci. 2025 Mar 27;26(7):3076. doi: 10.3390/ijms26073076. PubMed PMID: 40243780; PubMed Central PMCID: PMC11988776.
AÑO: 2025; IF: 4.9
|
|
Rodriguez-Martinez A, Giraldo-Ruiz L, Ramos MC, Luque I, Ribeiro D, Postigo-Corrales F, Alburquerque-Gonzalez B, Montoro-Garcia S, Arroyo-Rodriguez AB, Conesa-Zamora P, Hurtado AM, Luengo-Gil G, Perez-Sanchez H. Discovery of Z1362873773: a novel fascin inhibitor from a large chemical library for colorectal cancer. Sci Rep. 2025 Apr 28;15(1):14906. doi: 10.1038/s41598-025-96457-x. PubMed PMID: 40295602; PubMed Central PMCID: PMC12037858.
AÑO: 2025; IF: 3.8
|
|
Alburquerque-Gonzalez B, Montoro-Garcia S, Bernabe-Garcia A, Bernabe-Garcia M, Campioni-Rodrigues P, Rodriguez-Martinez A, Luque I, Salo T, Perez-Garrido A, Perez-Sanchez H, Cayuela ML, Luengo-Gil G, Luchinat E, Postigo-Corrales F, Staderini T, Nicolas FJ, Conesa-Zamora P. Monastrol suppresses invasion and metastasis in human colorectal cancer cells by targeting fascin independent of kinesin-Eg5 pathway. Biomed Pharmacother. 2024 Jun;175:116785. doi: 10.1016/j.biopha.2024.116785. Epub 2024 May 22. Erratum In: Biomed Pharmacother. 2024 Oct;179:117411. doi: 10.1016/j.biopha.2024.117411. PubMed PMID: 38781869.
AÑO: 2024; IF: 6.9
|
|
Garcia-Torralba E, Navarro Manzano E, Luengo-Gil G, De la Morena Barrio P, Chaves Benito A, Perez-Ramos M, Alvarez-Abril B, Ivars Rubio A, Garcia-Garre E, Ayala de la Pena F, Garcia-Martinez E. A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients. Front Oncol. 2023 May 29;13:1182725. doi: 10.3389/fonc.2023.1182725. eCollection 2023. PubMed PMID: 37313470; PubMed Central PMCID: PMC10258327.
AÑO: 2023; IF: 3.5
|